Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

New UC San Diego Health research shows a simple blood test could help doctors catch serious heart problems early.

Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...

Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from Merck, is raising awareness about one form of the condition: pulmonary arterial ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved sotatercept (Winrevair, Merck Sharp & Dohme) as a new treatment to improve exercise capacity in patients with pulmonary ...